Less than 10% of people that would benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it issues its first recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is urging increased and just availability to GLP-1 medication.
Per forecasts, over two billion will be living with obesity by 2030 without intervention.
"The new guidelines affirms that obesity is a chronic disease that can be managed with holistic and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to widespread availability to the jabs that can aid individuals in losing substantial body mass, notes the agency.
Skinny Jab Shortage
Even in the present best projected outlook, the supply of these medications might only reach about 100 million people – less than 10% of the global need, according to the health organization.
The advice urges countries and companies to increase access, via approaches including licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Injections Function
The injections imitate a natural hormone to delay gastric emptying, curb appetite and boost satiety so people reduce food intake.
Individuals commonly begin shedding pounds in the initial weeks of starting on the regular doses.
Studies points to patients may regain a significant portion after a year of halting the treatment, as their usual food cravings return.
Being carrying excess weight increases your likelihood for experiencing health problems, including type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity impacts people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
